SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019)

• M. Martín-Richard ^[1] ; A. Carmona-Bayonas ^[2] ; Ana. B. Custodio ^[3] ; J. Gallego ^[4] ; P. Jiménez-Fonseca ^[5] ; J. J. Reina ^[6] ; P. Richart ^[8] ; F. Rivera ^[9] ; M. Alsina ^[10] ; J. Sastre ^[7]
  1. [1] Hospital de la Santa Creu i Sant Pau

     Hospital de la Santa Creu i Sant Pau

     Barcelona, España

     
  2. [2] Hospital Morales Meseguer

     Hospital Morales Meseguer

     Murcia, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  5. [5] Hospital Universitario Central de Asturias

     Hospital Universitario Central de Asturias

     Oviedo, España

     
  6. [6] Hospital Universitario Virgen Macarena

     Hospital Universitario Virgen Macarena

     Sevilla, España

     
  7. [7] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  8. [8] Hospital Universitari i Politècnic la Fe
  9. [9] Hospital Marqués de Valdecilla
  10. [10] Hospital Universitario Vall D’Hebron

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 236-244
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Dialnet Métricas: 2 Citas
• Resumen

  • Gastric cancer (GC) is the fifth most common cancer worldwide with a varied geographic distribution and an aggressive behavior. In Spain, it represents the sixth cause of cancer death. In Western countries, the incidence is decreasing slightly, with an increase in gastroesophageal junction adenocarcinoma (GEJA), a different entity that we separate specifically in the guideline. Molecular biology advances have been done recently, but do not yet lead to the choice in treatment approach except in advanced disease with overexpression of HER2. Endoscopic resection in very early stage, perioperative chemotherapy in locally advanced tumors and preliminary immune therapy resulting in advanced disease are the main treatment innovations in the GC/GEJA treatment. We describe the different evidences and recommendations following the statements of the American College of Physicians.